Skip to main content
Premium Trial:

Request an Annual Quote

Avellino Lab AvaGen

Avellino Lab has launched AvaGen, a test that assesses risk for keratoconus and other corneal distrophies, with full nationwide availability in the US. According to the company, the test examines more than 2,000 variants in 75 keratoconus-related genes. The assay reports a keratoconus risk score that is intended to inform decisions around the use and timing of US Food and Drug Administration-approved cross-linking treatment, which can halt disease progression and preserve vision. AvaGen results can also influence an eye care professional's choice of refractive surgery options. 

For corneal dystrophies, the test determines the presence of any of the 70 TGFBI gene variants and provides a conclusive diagnosis of corneal dystrophy subtypes, such as epithelial basement membrane, granular and lattice disease distinctions, Reis-Bucklers, Schnyder and Theill-Behnke.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.